Literature DB >> 15262297

Management of the metabolic syndrome-nicotinic acid.

C Daniel Meyers1, Moti L Kashyap.   

Abstract

Nicotinic acid effectively treats each of the common lipid abnormalities found in the metabolic syndrome, and much progress has recently been made in understanding its mechanisms of action. Early concern that nicotinic acid can precipitate or worsen diabetes has been eased with recent trials, which demonstrated its safety and effectiveness in insulin-resistant states. Furthermore, nicotinic acid prevents cardiovascular disease and death in persons with a high prevalence of risk factors for the metabolic syndrome. When used by an experienced physician and taken by a motivated patient, nicotinic acid can be safe and effective in treating the dyslipidemia of the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262297     DOI: 10.1016/j.ecl.2004.03.014

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

1.  Mammalian colonocytes possess a carrier-mediated mechanism for uptake of vitamin B3 (niacin): studies utilizing human and mouse colonic preparations.

Authors:  Jeyan S Kumar; Veedamali S Subramanian; Rubina Kapadia; Moti L Kashyap; Hamid M Said
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-06       Impact factor: 4.052

2.  Are the effects of nicotinic acid on insulin resistance precipitated by abnormal phosphorous metabolism?

Authors:  Moutasim H Al-Shaer; Hatem S AbuSabha
Journal:  Lipids Health Dis       Date:  2004-10-28       Impact factor: 3.876

3.  Safety and tolerability of sauna detoxification for the protracted withdrawal symptoms of substance abuse.

Authors:  Richard D Lennox; Marie Cecchini-Sternquist
Journal:  J Int Med Res       Date:  2018-09-13       Impact factor: 1.671

Review 4.  Overviews of pathogen emergence: which pathogens emerge, when and why?

Authors:  S Cleaveland; D T Haydon; L Taylor
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.